Mineralys Therapeutics Reports Positive Phase 2 Trial Results

An update from Mineralys Therapeutics, Inc. ( (MLYS) ) is now available.

On June 17, 2025, Mineralys Therapeutics announced positive topline results from its Phase 2 Explore-CKD trial, which evaluated the safety and efficacy of lorundrostat in subjects with hypertension and comorbid CKD. The trial demonstrated significant reductions in systolic blood pressure and urine albumin-to-creatinine ratio, indicating potential renal protective effects and a favorable safety profile. These findings support the efficacy of lorundrostat and its potential role in managing hypertension and related kidney disease, further strengthening the company’s position in the cardiovascular therapeutic market.

The most recent analyst rating on (MLYS) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Mineralys Therapeutics, Inc. stock, see the MLYS Stock Forecast page.

Spark’s Take on MLYS Stock

According to Spark, TipRanks’ AI Analyst, MLYS is a Neutral.

Mineralys Therapeutics shows promise with positive clinical trial results and a strong cash position, but faces challenges with continuous losses and negative cash flows. Technical analysis suggests short-term momentum, while valuation remains a concern due to lack of revenue. The earnings call highlighted upcoming milestones that could enhance future prospects.

To see Spark’s full report on MLYS stock, click here.

More about Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines targeting hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA), and other cardiovascular diseases driven by dysregulated aldosterone.

Average Trading Volume: 946,630

Technical Sentiment Signal: Buy

Current Market Cap: $876.6M

Find detailed analytics on MLYS stock on TipRanks’ Stock Analysis page.